Swiss National Bank Has $398 Million Position in Gilead Sciences, Inc. $GILD

Swiss National Bank lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,585,600 shares of the biopharmaceutical company’s stock after selling 188,100 shares during the period. Swiss National Bank owned about 0.29% of Gilead Sciences worth $398,002,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Corundum Trust Company INC purchased a new stake in Gilead Sciences in the 3rd quarter worth about $26,000. Howard Hughes Medical Institute purchased a new position in Gilead Sciences during the 2nd quarter valued at about $30,000. MTM Investment Management LLC increased its holdings in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the period. Kilter Group LLC purchased a new stake in shares of Gilead Sciences in the second quarter worth approximately $33,000. Finally, Millstone Evans Group LLC lifted its position in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This represents a 1.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 309,280 shares of company stock worth $43,935,470. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on GILD. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Royal Bank Of Canada raised their price target on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 11th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Oppenheimer increased their price objective on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Finally, Citigroup reiterated a “buy” rating on shares of Gilead Sciences in a research note on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $156.72.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $144.08 on Monday. The stock has a market capitalization of $178.86 billion, a P/E ratio of 21.28, a P/E/G ratio of 1.89 and a beta of 0.36. The business has a 50-day moving average of $138.29 and a two-hundred day moving average of $125.85. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.3%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio is 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.